摘要
目的 探讨Fas配体 (FasL)在人类非小细胞肺癌 (NSCLC)中的表达及临床意义。方法 应用免疫组织化学方法检测FasL蛋白在 32例手术切除的NSCLC中的表达情况。结果 FasL在本组 32例NSCLC中的阳性表达百分数为 3.0 %～ 98.7% ,平均(6 2 .0± 32 .0 ) % ,其中在肺腺癌中的平均阳性表达百分数为 (80 .5± 2 1 .2 ) % ,在肺鳞癌中为 (5 2 .3± 32 .8) % ,FasL蛋白在两种不同病理类型的肺癌中阳性表达水平差异显著 (P <0 .0 5 )。但在不同分化程度和不同外科病理分期 (PathologicalTNMstage ,pTNM)的NSCLC中FasL蛋白表达差异不显著 (P >0 .0 5 )。结论 FasL在NSCLC中的表达提示NSCLC具有反杀伤免疫细胞的能力 。
Objective To explore the expression of Fas ligand (FasL) protein in human non small cell lung cancer (NSCLC) and its clinical significance. Methods Expression of FasL protein was detected by immunohistochemical method in 32 resected tumors of NSCLC. Results FasL protein was detected in all of these 32 resected tumors with variant positive expression levels ranging from 3.0% to 98.7% [mean (62.0± 32.0)% ]. There was significant difference between the tumors of different pathological types no significant difference was found between the tumors of different differentiation nor among the tumors of different pTNM stages (P>0.05). Conclusion The results indicated that NSCLC can counterattack the immune cells of the body and may be the molecular basis for the easily metastasis of adenocarcinoma to in the early stage.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2001年第5期530-532,共3页
Journal of Third Military Medical University
